Cancer Vaccines

SensiGen Exercises Option to Ultra-Sensitive Human Papillomavirus (HPV) Test

Published in Cancer Weekly, March 6th, 2007

SensiGen LLC, a biotechnology company focused on developing proprietary gene-based molecular diagnostics announced that it has exercised its option to exclusively license an ultra-sensitive Human Papillomavirus - HPV detection test developed at the University of Michigan.

The technology, called the AttoSense(TM) HPV Test, was developed in the laboratory of David Kurnit, MD, PhD, Professor of Pediatrics and Communicable Diseases at the University of Michigan Medical Center. "With this technology we have demonstrated the ability not only to detect as little 1 to 3 copies of HPV DNA in any blood or tissue sample, but also to clearly identify in a single assay each of the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2007-03-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry